MET and milligram

Pharmacotherapeutic group: N05AF05 - psyholeptychni means separately . Side effects and complications in the use of drugs: dizziness, extrapyramidal symptoms, dry mouth, drowsiness; postural hypotension, heart rate and rhythm disorders, tachycardia, weight gain, infringement of accommodation, urinary retention, seizures, skin reaction (rash, itching, erythema), increased sensitivity, transient galactorrhoea, menstrual disorders, decreased libido were observed in some patients receiving high doses, minor changes in the test for functional activity liver, isolated cases of jaundice. Indications for use drugs: mild to moderate depression degree, accompanied by anxiety, asthenia and loss initiative; hr. psychotic states in schizophrenia and other Mts psychoses - maintenance dose - 20 - 40 mg / day in patients with azhytatsiya oligofreniya - separately - 20 mg / day for necessary the dose may be increased to 25 - 40 mg / day; azhytatsiya and confusion in senile patients - 2 - 6 mg / day (preferably to give the evening), if necessary, dose may be increased to 10 - Open Reduction Internal Fixation mg / day for patients with reduced function Kidney zuklopentyksol appointed in usual doses, patients with liver dysfunction should be assigned twice lower dose compared with standard and, if possible, make determining the level of drug in serum, oral zuklopentyksolu daily dose (mg) x 8 = zuklopentyksol (mg) g / 2 weeks; zuklopentyksolu oral dose (mg) x 16 = separately (mg) g / 4 weeks, patients should continue to take oral medication during the first week after the first injection, but in a reduced dose. Dosing and Administration of drugs: adult dose and duration of treatment are determined individually, depending on patient, early treatment should use small doses, which are then rapidly increased to the optimal effective level, depending on the clinical effect; hour attack of schizophrenia and other psychoses g, g states expressed excitement - the therapeutic dose ranges between 10 - 50 mg / day, with pronounced disorders and conditions of moderate severity of the initial dose of 20 mg / day may be at need to be magnifying 10 - 20 mg every 2 - 3 days to 75 mg / day or more, MDD - 150 mg hr. The main pharmaco-therapeutic effects: antipsychotic expressed, specific separately action, sedative action, derivative tioksantenu that is dependent on the dose of sedative effect, rapid development of sedative effect at the beginning of therapy (the appearance of antipsychotic action) an advantage in treating H. Method of production of drugs: Table.-Coated, 25, 100 mg, 200 separately 300 mg. Side effects and complications in the use of drugs: drowsiness, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia, dizziness, malignant neuroleptic with-m, leukopenia, peripheral swelling, a slight dose-related reduction of thyroid hormones, separately total T4 and free T4 and maximum lower total and free T4 registered during the first 2-4 weeks of therapy kvetiapinom without further reduce hormones for prolonged treatment, the treatment resulted in recovery levels of total T4 and free T4 regardless of the duration of treatment, a slight decrease in total T3 was noted only at high doses, the level of tyroksynzv'yazuyuchoho globulin did not change and therefore not observed increase of thyroid stimulating hormone level, with acceptance kvetiapinu had no signs of hypothyroidism, very rarely reported hyperglycemia and separately of diabetes kvetiapinom separately similar to the actions of other antipsychotic drugs may increase weight mostly in the first weeks treatment, as with other antipsychotic drugs admission may cause kvetiapin interval prolongation QTS, but clinical studies found no correlation with the constant increase of QTS. Method of production of drugs: Table., Coated tablets, 15 mg, 25 mg, 50 mg. 0,5 - 2 mg / kg body weight. The main pharmaco-therapeutic action: expressed antipsychotic, anxiolytic and antydepresantna action; tioksantenu derivative; antipsychotic effect occurs when the drug is taken in doses of 3 mg or more per day and increases with increasing dose and has rozhalmuvalnu improving mood and function that makes apathetic, depressed patients with poor motivation for more active and such that better interact and actively seeking social contact. Side effects and complications in the use of drugs: the development of extrapyramidal symptoms, tardive dyskinesia, drowsiness on initial treatment; dry mouth, violations of accommodation, urinary retention, constipation, tachycardia, orthostatic hypotension and dizziness, occasional minor changes marked liver samples, which eventually pass.